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Abstract
Background: South Africa is among the seven highest tuberculosis (TB) burden countries. Harmful lifestyle behaviours,
such as smoking and alcohol, and poor adherence to medication can affect clinical outcomes. Modification of these
behaviours is likely to improve TB treatment outcomes and has proven possible using motivational interviewing (MI)
techniques or use of short message service (SMS) text messaging. There have been no studies assessing the effect of
combined MI and SMS interventions on multiple lifestyle factors and TB treatment outcomes.
Methods: This is a prospective, multicentre, two-arm individual randomised controlled trial looking at the effectiveness
and cost-effectiveness of a complex behavioural intervention (the ProLife programme) on improving TB and lifestyle-
related outcomes in three provinces of South Africa. The ProLife programme consists of an MI counselling strategy,
delivered by lay health workers, augmented with subsequent SMS. We aim to recruit 696 adult participants (aged 18
years and over) with drug-sensitive pulmonary TB who are current smokers and/or report harmful or hazardous alcohol
use. Patients will be consecutively enrolled at 27 clinics in three different health districts in South Africa. Participants
randomised individually to the intervention arm will receive three MI counselling sessions onemonth apart. Each MI
session will be followed by twice-weekly SMS messages targeting treatment adherence, alcohol use and tobacco
smoking, as appropriate. We will assess the effect on TB treatment success, using standard World Health Organization
(WHO) treatment outcome definitions (primary outcome), as well as on a range of secondary outcomes including
smoking cessation, reduction in alcohol use, and TB medication and anti-retroviral therapy adherence. Secondary
outcomes will be measured at the three-month and six-month follow-ups.
Discussion: This trial aligns with the WHO agenda of integrating TB care with the care for chronic diseases of lifestyle,
such as provision of smoking cessation treatments, and with the use of digital technologies. If the ProLife programme
is found to be effective and cost-effective, the programme could have significant implications for TB treatment globally
and could be successfully implemented in a wide range of TB treatment settings.
Trial registration: ISRCTN Registry, ISRCTN62728852. Registered on 13 April 2018.
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Background
South Africa has the second highest incidence of tuber-
culosis (TB) and the sixth highest TB burden of the 30
high TB burden countries. It also has a high prevalence
of human immunodeficiency virus (HIV) co-infection in
patients with TB and a high mortality in these co-
infected patients relative to most other high-burden
countries [1]. In addition to HIV co-infection, a range of
social, psychological and economic factors influence
treatment success in TB. Of these, tobacco smoking and
hazardous or harmful alcohol use are specifically men-
tioned in the South Africa National TB Management
Guidelines [2]. Tobacco use and problem drinking are
prevalent in TB patients, often co-occur [3–5] and are
known to increase the risk of death and poor treatment
adherence and outcomes [6–9].
As well as increasing the risk of TB infection and pro-
gression of disease [10], smoking is also known to in-
crease the risk of treatment failure [11], relapse [12, 13]
and death [14], and is associated with resistance to iso-
niazid, one of the main antimicrobials used to treat TB
[15]. There is evidence that patients who stop smoking
have better TB treatment outcomes and, if co-infected,
better HIV treatment outcomes than current smokers
[16–18]. In addition, alcohol misuse is associated with
poorer TB outcomes through a range of mechanisms in-
cluding decreased effectiveness of medications used to
treat TB (including drug resistance), increased recur-
rence and treatment default rates and social marginalisa-
tion [3]. It has been estimated that 10% of the global
burden of TB is attributable to alcohol use [19, 20].
Poor adherence to TB medication and anti-retroviral
therapy (ART) significantly increases the risk of adverse
effects and death in TB patients. Strategies are needed to
improve medication adherence in TB-HIV co-infected
patients, in whom integration of TB and HIV care has
been shown to decrease mortality [21].
A number of studies have attempted to evaluate the
effectiveness of tobacco cessation, alcohol reduction
or TB treatment adherence interventions in TB pa-
tients [21, 22], but few have assessed the effect on
TB treatment outcomes [23, 24]. We know that brief
smoking cessation interventions, ranging from oppor-
tunistic advice and proactive telephone support
through to in-person behavioural support over mul-
tiple sessions, are effective and affordable in low-
income countries, in both TB patients and smokers in
the general population [25, 26]. We also know that
disease diagnosis could constitute a ‘teachable mo-
ment’, when people are more amenable to advice and
motivated to modify harmful lifestyle behaviours [27].
For this reason, it is likely that patients receiving a
TB diagnosis may be more successful in quitting
smoking and moderating alcohol use if offered
behavioural support, compared with smokers and
problem drinkers in the general population.
Motivational interviewing (MI) is a counselling tech-
nique known to facilitate behaviour change [28], which
has demonstrated effectiveness for the reduction of haz-
ardous drinking, tobacco cessation, and TB treatment
and/or ART adherence [19, 29, 30]. Our group has had
previous success in achieving sustained smoking abstin-
ence in TB patients through a brief MI intervention de-
livered by lay health workers (LHWs) [31]. There is also
evidence to suggest that adherence to ART [32] and pos-
sibly TB medication [33], as well as tobacco cessation,
can be enhanced with the use of short message service
(SMS) text messages on mobile phone technology [34].
To our knowledge, no study has used MI in combination
with SMS text messages to address multiple harmful be-
haviours that adversely impact TB outcomes.
The ProLife programme is a novel complex behav-
ioural intervention targeting tobacco smoking, problem
drinking, and TB and HIV medication adherence in pa-
tients with TB. This is the study protocol for the rando-
mised controlled trial (RCT) aiming to assess the
effectiveness and cost-effectiveness of the ProLife
programme in improving TB treatment outcomes in pri-
mary healthcare clinics located in high TB-burden com-
munities in three provinces in South Africa (Gauteng,
Free State and North West). The protocol has been writ-
ten in accordance with the Standard Protocol Items:
Recommendations for Intervention Trials (SPIRIT)
guideline.
Methods/Design
Objectives
The primary objective is to assess the effectiveness and
cost-effectiveness of the ProLife programme compared
to usual care in improving pulmonary TB (PTB) treat-
ment outcomes. We also aim to assess the effectiveness
and cost-effectiveness of the programme in achieving ab-
stinence from smoking, reducing harmful and hazardous
drinking, and improving TB and ART medication
adherence.
Trial design and setting
This is a pragmatic, prospective, multicentre, two-arm,
parallel, individual RCT taking place in 27 purposively
selected primary care clinics with the highest TB case-
load in three districts in South Africa: Welkom in the
Free State; Bojanala in the North West province; and
Sedibeng in Gauteng province. To be eligible for inclu-
sion in the trial, TB clinics had to be under the control
of the provincial or local government (i.e. not a mining
TB clinic). The intervention will be delivered by LHWs
and three district coordinators who will each cover 1–2
clinics.
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Participants will be randomly allocated to one of two
arms:
Arm 1: Intervention arm – participants in the
interventions arm will receive the ProLife programme;
Arm 2: Control arm – participants will receive usual
treatment and support provided to TB patients in TB
treatment clinics in South Africa (‘usual care’).
Intervention
The ProLife programme is a complex behavioural inter-
vention aimed at improving treatment outcomes in TB
patients who smoke tobacco, drink alcohol at harmful or
hazardous levels, or do both. The ProLife programme
has been developed in line with the Medical Research
Council (MRC) guidance on developing and evaluating
complex interventions [35] and has undergone a period
of development and feasibility testing in South Africa.
The paper reporting the results of this evaluation has
not yet been published. The conceptual framework used
to develop the ProLife programme assumes that smok-
ing cessation, reducing harmful alcohol use and im-
proved adherence to TB and HIV treatment will result
in improved TB treatment outcomes.
Participants randomised to the intervention arm will re-
ceive three brief MI counselling sessions, lasting 15–20
min, each onemonth apart, from a trained LHW at their
TB clinic. In the initial MI session, occurring at the start
of TB treatment, the counsellor will establish the partici-
pant’s tobacco smoking habits and problem drinking; po-
tential obstacles and facilitators for medication adherence
or treatment initiation (both TB treatment and ART)
will be determined. The participant will determine
which factor should be prioritised (i.e. agenda setting),
which could be a plan either to quit tobacco smoking,
reduce or quit drinking or deal with barriers relating
to ART or TB medication adherence. For participants
who are HIV-infected and not yet on ART, beliefs
and attitudes regarding HIV-testing or ART will be
explored to facilitate ART initiation and adherence.
The second session will build on the previous one
and will focus on the previous agenda before moving
on to the next behavioural problem (tobacco, alcohol
or medication adherence) where applicable. The third
session will deal with the last identified problem.
The individual counselling sessions will be re-enforced
with SMS text messages regarding information, motiv-
ation and behaviours (IMB) supporting tobacco cessa-
tion, alcohol use and medication adherence. Text
messages will be delivered twice a week over 12 weeks.
All participants will first receive 10 TB-related messages.
These messages will be followed by seven alcohol or
smoking-related messages depending on whether the
participant smokes or drinks. Co-joint users will receive
all sets of messages (i.e. 24 in total).
Comparator
Participants in the second group are the controls and
will receive usual TB treatment and support offered to
TB patients. Control participants are seen by a TB nurse
and receive the same biochemical investigations and
medical treatments as the intervention arm. However,
they will not receive the MI and SMS package of care as
described above. Usual care also includes HIV testing
with pre- and post-test HIV test counselling by a lay
counsellor or a nurse (this varies by district).
In addition, health education is given on:
 nature of TB, treatment adherence, treatment side-
effects/complications, drug interactions, tobacco use,
alcohol use and other substance abuse. This is
mostly done by the TB nurses, is not intensive and
is educational in nature rather than a form of
counselling;
 healthy diet by a dietician where possible;
 social problems and family support for treatment by
a social worker as needed and depending on the
availability of social workers; and
 point of care blood glucose, haemoglobin and
pregnancy tests are performed. If co-infected with
HIV, a full blood count, liver function test and
creatinine are also carried out.
Participants
The inclusion criteria for participants are:
 adult patients (aged ≥ 18 years) with drug-sensitive
(bacteriologically or clinically confirmed) PTB;
 initiating TB treatment or on TB treatment for < 1
month (these include both ‘new’ and ‘retreatment’
patients);
 current smokers and/or hazardous/harmful drinkers
who are not alcohol dependent (Alcohol Use
Disorders Identification Test [AUDIT] score ≥ 8 for
men or ≥ 7 for women but < 20);
 access to a functional mobile phone; and
 understands one of the four languages used for the
trial (Sesotho, Setswana, Isizulu or English).
Exclusion criteria:
 alcohol-dependent participants (AUDIT score ≥ 20);
 Extrapulmonary TB without PTB; or
 Resistance to one or more TB drugs at baseline
(because drug-resistant TB needs further investigations
which take several months and is treated through
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a long, specialised treatment programme if
present).
Recruitment process
Participants will be recruited consecutively from the
starting date of the trial until the required sample size
for each clinic has been achieved. The sample size per
clinic will vary depending on the workload for each
clinic. TB patients who initiate treatment (or who have
been on treatment for < 1 month) will be asked if they
would like to participate. If they agree, they will then be
screened for eligibility by trained fieldworkers immedi-
ately after the TB nurse at the clinic has initiated TB
treatment and started the routinely used TB treatment
record. Eligibility screening will involve being assessed in
line with the inclusion criteria listed above and being
asked about their:
 smoking status: using the Global Adult Tobacco
Survey [36] questionnaire, patients will be asked
whether they currently smoke daily, less than daily
or not at all, and in the past daily, less than daily or
not at all. As TB patients in South Africa often
smoke little or may not have smoked for a few days
because of ill-health and the word ‘current’ is open
to interpretation (particularly when translated);
‘current’ has been defined as smoking daily and non-
daily in the last four weeks for the purpose of this
study. Smoking habits will be further quantified at
baseline interview;
 current alcohol usage: AUDIT, a validated tool for
identifying problem alcohol behaviours [37], will be
used to quantify alcohol intake. Those with an
AUDIT score ≥ 8 for men or ≥ 7 for women but < 20
will be eligible for the trial.
If eligible, patients will be invited to join the trial. For
those who wish to be enrolled into the trial, written in-
formed consent will be obtained (Additional file 1).
Randomisation and allocation
Patients will be randomised using a randomised se-
quence generator performed by the trial statistician
(MK) who will remain blind to the arm allocation. We
will use block randomisation with varying block sizes
stratified by the clinic to achieve equal numbers in inter-
vention and control groups within each clinic (see the
‘Sample size’ section). Allocation concealment will be
done with consecutively numbered, sealed, opaque
envelopes.
Ethics and consent
Potential participants will be approached and given an
introduction to the study and basic eligibility criteria
required for participation. Participants who meet the eli-
gibility criteria for language, age, PTB, treatment dur-
ation and mobile phone access will be given a consent
form (Additional file 1) to sign before screening for alco-
hol and tobacco use eligibility as the alcohol-related
questions are sensitive and the fieldworkers must ac-
cess the patient treatment record. If recruited to the
trial, participants will be ask to consent to enter the
trial, including consent for audio recording of the MI
counselling sessions (Additional file 1). A witness sig-
nature will be required where the participant is un-
able to read or write.
The identity of participants will be protected by allo-
cating each participant a unique trial number, which will
be used on all research documents and will ensure ano-
nymity for the data analysis. Participation will be volun-
tary; participants will be informed of their right to
withdraw from the study at any time without giving a
reason for their withdrawal. The project is unlikely to be
directly harmful to TB patients with the exception of in-
convenience in terms of time spent on the counselling
sessions. Participants will receive ZAR 60 (US$4.19)
travel and other expenses reimbursement for each MI
counselling session and follow-up visit related to the
study.
Timeline and procedures
Figure 1 Additional file 4 outlines the overall participant
flow through the trial. Eligible and consenting patients
will be enrolled in the trial and the baseline interviewer-
administered questionnaire and record review com-
pleted. Participants will receive a baseline interview on
the same day as the recruitment or on the nearest avail-
able date suitable to both the participant and the LHW.
The initial part of the questionnaire covers socioeco-
nomic and demographic factors. We will also assess for
depression using the CES-D10 [38], a validated tool, as
depression may be a potentially moderating or mediating
factor affecting treatment outcome. See Additional file 2
for the full case report form (CRF).
The next part will cover medical history, particularly
TB and HIV history and current medications. Partici-
pants identified as current smokers at eligibility screen-
ing will be asked more in-depth about their smoking
habits and quit history. All participants will be asked
about their use of smokeless tobacco and exposure to
second-hand smoke. Participants will also be asked
about time and money spent on TB-related healthcare
visits in the past three months and health-related quality
of life (see the ‘Economic evaluation’ section). After ad-
ministering the baseline interviews, fieldworkers will
draw the allocation envelopes and organise the
follow-up sessions for the participants. Each of the in-
terviews on health status, tobacco and alcohol use at
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baseline, three months and six months is not expected
to last > 25 min.
Primary outcome
The primary outcome is TB treatment success at 6–9
months of follow-up, measured using the routinely col-
lected programmatic TB treatment outcomes as defined
by the World Health Organization (WHO) and adopted
in South Africa. This is a binary variable defined as
either successful treatment (cured or treatment com-
pleted) or failed treatment, death, acquired drug resist-
ance, loss to follow-up or ‘default’, or not outcome
evaluated. Table 1 defines the different treatment outcomes
according to the South African Department of Health
National Tuberculosis Management Guidelines [2].
Individual TB treatment records will be used as the
primary source of information. The TB treatment rec-
ord is the routinely used clinical document initiated
by the TB nurse when the patient first presents at the
TB clinic and includes demographic information as
well as a comprehensive overview of the patient’s
treatment over time. The TB treatment outcomes will
be obtained 6–9 months after the TB treatment start
dates. This is to allow for short periods of treatment
interruption and time needed to confirm the TB
treatment outcomes status. For example, the TB nurse
may have to wait for end of treatment TB sputum or
culture results or time may be required to determine
whether a participant died. In some cases, TB patients
may also undergo a longer TB treatment regimen.
Routinely reported outcomes will be verified for cor-
rectness by checking the actual individual diagnosis and
treatment records. For example: if the outcome is classi-
fied as cured, then the criteria for diagnosis and out-
come definitions should have been adhered to. Attempts
will be made to verify the information of patients classi-
fied as ‘defaulted’ or who are lost to follow-up by con-
tacting them telephonically or sending them a short text
message. Sputum cultures and smears will be performed
at baseline, twomonths, three months and six months
per routine care.
Secondary outcomes
The following outcome measures will also be recorded
at the six-month follow-up:
 sputum conversion at the end of treatment: this will
be measured by negative culture or smears in the
group of participants who had bacteriology
confirmed PTB at baseline, i.e. cure rates in
intervention group versus control group for
participants who initially had sputum AFB-positive,
culture-positive or GeneXpert-positive PTB;
 six-month continuous smoking abstinence: the
Russell Standard defines continuous abstinence as a
self-report of not smoking > 5 cigarettes from the
Fig. 1 CONSORT Flow diagram outlining randomisation and participant recruitment
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start of the abstinence period (in this case, six
months), supported by a negative biochemical test
(exhaled carbon monoxide [CO] < 10 ppm) at final
follow-up [39]. For the purpose of our study, we
will, however, use a more stringent criterion of
exhaled CO < 7 ppm, based on findings from our
previous study that some participants who
reported continued smoking had an exhaled CO
< 10 ppm [26]. This analysis will be performed on
the group of participants who were current to-
bacco smokers at baseline;
 reduction in harmful or hazardous drinking:
alcohol use will be measured using the AUDIT
questionnaire. The questionnaire will be
administered at screening (which will take place
on the same day or shortly after the baseline
assessment) and again at three months and six
months. Changes in the total AUDIT score will
be used to compare change in drinking behaviour
between control and intervention groups. This
analysis will be performed on the group of
participants who were harmful or hazardous
drinkers at baseline.
 TB and ART medication adherence: adherence to
both TB and ART medications will be measured
using a modified version of the AIDS Clinical Trials
Group (ACTG) Adherence Questionnaire. The
questionnaire is a validated tool for measuring
adherence specifically to ART and we will use an
adapted version to also measure TB medication
adherence [40]. Field workers will administer the
baseline part of this questionnaire as part of the
baseline CRF and adherence will be measured at
both three months and six months.
Adherence will be measured using an adherence index
calculated by the formula (using the four-day recall
table):
Total number of doses taken=Total number of doses prescribed½  x 100
ART patients with at least 95% of adherence will be
considered as having optimal adherence and those with
< 95% will be considered as having low (or suboptimal)
adherence. For the TB medication regimen, patients with
at least 95% of adherence will be considered as having
optimal adherence and those with < 95% will be consid-
ered as having low (or suboptimal) adherence:
 increase in proportion of HIV-positive participants
on ART: HIV status will be recorded in the TB
Treatment Record. HIV-positive participants will be
asked about ART status at baseline, three months
and six months using standardised questions on the
CRF.
The following outcomes will be measured at three
months:
 biochemically verified three-month sustained to-
bacco cessation;
 reduction in harmful or hazardous drinking;
 TB drug and ART adherence;
Table 1 Definitions for TB treatment outcomes according to the South African Department of Health National Tuberculosis
Management Guidelines
Treatment
outcome
Definition
Cure Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last
month of treatment and on at least one previous occasion at least 30 days prior
According to local protocol, a patient who is diagnosed using Gene Xpert and is sputum negative for TB at 11 and 23 weeks is
considered ‘Cured’.
Treatment
completed
Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a
negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed
with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological
findings who have shown clinical improvement and completed the prescribed course of treatment.
N.B. The smear examination may not have been done or the results may not be available at the end of treatment.
Treatment failure Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during
treatment.
Patients who were negative at baseline but were later found to be positive.
N.B. This definition excludes those patients who are diagnosed with RR-TB or MDR-TB during treatment.
Died Patient who dies for any reason during the course of TB treatment.
Treatment default Patient whose treatment was interrupted for two consecutive months or more during the treatment period.
Transfer out Patient who was referred to a facility in another district to continue treatment and for whom the treatment outcome is not
known.
Acquired
resistance
Participants who are subsequently referred for MDR treatment.
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 increase in proportion of HIV-positive participants
on ART.
The schedule for enrolment, intervention and assess-
ments is presented in Fig. 2. Table 2 summarises the
methods of data collection and analysis for each of the
primary and secondary outcomes.
Data collection and management
Data will be collected and recorded by field workers
equipped with Android phones with a mobile data col-
lection application installed. MI counselling and data
collection will take place in a well-ventilated private area
inside or outside the clinic (but within the grounds of
the health facility); MI sessions will be audio-recorded
where consent has been obtained. Fieldworkers and
LHWs will be provided with high particulate respirator
masks to minimise the risk of infection.
Fieldworkers will follow-up all participants in both
arms at three and six months within a window period of
two weeks before and two weeks after the ideal three-
month and six-month visit. Participants will receive SMS
reminders three days before each planned visit. Partici-
pants will also be in a position to send ‘please call me’
messages to the district coordinators, who will then call
the participant to solve problems that may have arisen
with the appointment.
The electronic data captured will be stored on secured
and password-protected storage servers and mobile
phones which ensure data privacy through only allowing
authorised research staff access to the data. The elec-
tronic data collection system used for the study requires
an SMS gateway to send and receive messages to the re-
search participants. Consenting participants’ phone
numbers, participant IDs and associated SMS messages
will be stored on the SMS gateway’s secured and
password-protected server.
Data quality will be ensured by providing fieldworkers
with standard operating procedures (SOPs), training and
ongoing support on the importance of data quality, data
collection and data collection problem solving. Training
will consist of a four-day session before the commence-
ment of the pilot and a one-day training session focusing
on problems identified during the pilot preceded the
trial. The data manager will continuously monitor the
captured data for missing variables and inconsistencies
in order to resolve any data problems.
The data manager will export the data from the se-
cured server, conceal the participants study arm alloca-
tion and de-identify the data before sharing the data in
STATA and R compatible formats. The exported de-
identified data will be stored in Dropbox, a secure cloud
storage platform, for sharing with the lead trial statisti-
cian at the University of York for analysis.
All research data and documents referring to the
ProLife trial will be stored and maintained in a secured
storage space at SMU for a minimum of 15 years from
the end of the ProLife trial. Study materials will be
destroyed 15 years after the study.
Blinding and limitation of risk of bias
This is a complex behavioural intervention and the
team dynamics mean that all team members work
very closely with one another. As such, LHWs and
participants cannot be blinded to the intervention.
The determination of the primary outcome will be
done by the TB nurses who are blinded to the inter-
vention status of the participants based on routinely
collected data. Blinding of the field researchers col-
lecting other questionnaire data (Additional file 2)
Fig. 2 SPIRIT Figure outlining data collection throughout trial
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will not be possible. The statistician will be blinded
to the intervention or control arm allocation of par-
ticipants during the analysis stage.
There is a potential of biased outcome reporting on
self-reported tobacco smoking or alcohol consumption
favouring the intervention arm. This will be minimised
by training the fieldworkers in open communication and
standardised data collection. Tobacco cessation will also
be verified by exhaled CO monitoring. Given the use of
the TB treatment record as a primary source of informa-
tion pertaining to TB outcomes, there is a risk of non-
differential misclassification. However, this risk is equal
in both the treatment and control arms and therefore
the decision has been taken that the TB treatment rec-
ord can be used as a primary data source (i.e. bias would
be towards the null).
Sample size
The sample size has been set at 696 participants (348 par-
ticipants per arm). This sample size is sufficient to
detect a 10% difference in TB treatment success rates
(0.86 vs 0.76) in the ProLife group versus the control
group with 80% power, a significance level of 0.05
and 25% attrition. The sample size per clinic was in
the range of 14–74 participants per clinic with a me-
dian of 24. The assumed success rates in the control
group are based on actual success rates in TB pa-
tients in the studied provinces.
Statistical analysis
We will summarise baseline data descriptively by trial
arm; however, we will not undertake statistical compari-
sons. For continuous measures, we will report means
and standard deviations (SD); for skewed data, we will
also provide medians and interquartile ranges. For cat-
egorical data, we will report counts and percentages. For
the primary outcome, we will conduct analysis on an
intention-to-treat basis. We will use binary logistic re-
gression to compare the main outcome between the
intervention and the usual care arm.
We will carry out similar analyses for the secondary
outcomes with appropriate regression techniques: logis-
tic regression for categorical outcomes and linear regres-
sion for continuous outcomes. We will also adjust for
baseline characteristics and other covariates (HIV status,
sex, alcohol versus tobacco versus both, district) if these
differ between trial arms at baseline.
In case of missing data, we will employ a number of
methods including multiple imputations to assess the
sensitivity of the results. We will conduct subgroup ana-
lyses to determine whether TB treatment outcomes dif-
fer between subgroups, as follows: HIV-positive versus
HIV-negative participants; participants with an alcohol
problem only versus smokers only versus participants
who are conjoint smokers and drinkers; and participants
who were GeneXpert positive versus participants who
were GeneXpert negative at baseline.
Table 2 Summary of methods of data collection and analysis for primary and secondary outcomes
Variable Method of data collection Method of data analysis
Primary outcome: TB treatment outcome as
defined by WHO and the South Africa TB
Management Guidelines (see Table 1)
• CRF and TB treatment record
• Treatment outcome as recorded by TB nurses in TB
cards using the standard WHO definitions of cure,
completions, failure, death, TB treatment
interruption, drug resistance developed in course of
treatment (confirmed for correctness by checking
sputum culture/smear at baseline, at 5 and 6
months)
Binary outcome: successful (cured of
completed) vs not successful (died, failure,
treatment interruption, drug-resistant TB)
All participants, excluding those transferred out
Secondary outcome: sputum conversion • Sputum culture/smear at baseline, 5 and 6months
to determine cure rates for PTB patients who had a
positive smear or culture at baseline
• Sputum conversion at 2–3 months
Binary cured vs not cured for the subgroups of
participants who had a positive smear/culture
at baseline
Binary conversion vs not for the subgroups of
participants who had a positive smear/culture
at baseline
Secondary outcome: change in smoking
behaviour
• CRF – questions as per Russell’s Standard – baseline
smoking behaviours and then at 3 and 6months
• Exhaled carbon monoxide reading at 3 and 6
months
Binary outcome validated 3 and 6months
sustained smoking cessation for the subgroup
of participants who were smoking at baseline
Secondary outcome: percentage reduction
in harmful or hazardous drinking (change in
AUDIT score)
• AUDIT score at baseline and at 3 and 6months Change in AUDIT score (continuous) for
subgroups of participants who were hazardous
or harmful drinkers at baseline
Secondary outcome: HIV and TB medication
adherence
• CRF – questions modified from ACTG Binary outcome (% adherent vs non-adherent)
Secondary outcome: proportion of HIV-
positive participants on ART
• HIV status at baseline
• ART status at baseline, 3 months and 6 months
Binary on ART vs not on ART for the subgroup
of HIV-positive participants, taking into account
baseline % on ART
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We will follow the CONSORT statement guidelines
in reporting. We will use the statistical packages
STATA and R to carry out the analyses and a P value
< 0.05 will be considered as statistically significant.
The statistical analysis pertaining to cost-effectiveness
will be described in the section detailing the planned
economic evaluation.
Monitoring
Each centre will be responsible for its own data entry
and local trial management. Monitoring and site training
will be carried out at each site within specified intervals.
The project manager will visit each district every third
month with the counselling supervisor. The district co-
ordinators will visit each clinic bi-weekly; the site leads
and data manager will visit the sites when required.
The monitoring will adhere to the principles of Good
Clinical Practice and will follow an agreed monitoring
plan. During their bi-weekly visits, the district coordina-
tors will be guided by a checklist to confirm adherence
to protocol, review eligibility verification and consent
procedures, and provide additional training as needed.
Any adverse events will be formally recorded and re-
ported where appropriate.
The mobile data collection tool was improved based
on findings from the pilot phase and feedback from the
field staff capturing the data. Validation was added to
the mobile questionnaires to ensure that all questions
should be answered, participants only answer question
relevant to them and that no unusual values (range
checks) are entered. Coordinators can use the mobile
data collection tool on their phones to monitor incom-
plete data activities, outstanding and upcoming appoint-
ments with participants and basic project performance
indicators per clinic.
The data captured during the interviews with the par-
ticipants are only captured on the electronic mobile data
collection tool and can therefore not be verified by the
site coordinators. However, the district coordinators will
require access to all (enrolled TB) patient medical re-
cords including, but not limited to, laboratory test re-
sults and prescriptions. They will do spot checks by
comparing the captured data with the medical records
and look for missed outcomes reporting: verify com-
pleteness; consistency; and accuracy of data being en-
tered on CRFs. The site leads (or delegated personnel)
should work with the district coordinators to ensure that
any problems detected are resolved.
The data will also be checked by the data manager for
missing or unusual values (range checks) and checked
for consistency within participants over time. If any such
problems are identified, the individual centres will be
contacted and asked to verify or correct the entry.
Indicators related to enrolment, premature withdrawal,
motivational interviewing completion, CRF completion
and SMS delivery will be analysed and included in
monthly reports.
As the ProLife programme is a low-risk intervention,
the decision was taken not to appoint an external data
monitoring committee.
Training and intervention fidelity monitoring
Eighteen LHWs, three district coordinators and one per-
son who will be focusing on counselling supervision
underwent MI training over five days, which covered:
basic knowledge of TB; treatment adherence; tobacco
and alcohol use; overview of the overall spirit of MI and
communication style; core interviewing skills; evoking
change talk, hope and confidence; developing a change
plan; and strengthening commitment. The LHWs’ know-
ledge in terms of TB, alcohol use, tobacco smoking, TB
and ART treatment adherence, and motivational inter-
viewing was assessed before and after the training
To ensure that all the essential steps, techniques and
skills of an MI session are covered during each session,
the LHWs will be provided with a checklist to use dur-
ing each session (Additional file 3). At the end of each
session, they will also complete a post-session semi-
structured form onto which they will indicate the extent
to which they implemented each element of MI, as well
as their general qualitative impressions of that particular
session.
During the trial, the LHWs will receive regular super-
visory support from the district and national study coor-
dinators. In addition, an appointed supervisor with
proficiency in MI will be providing monthly counselling
supervision to the LHWs in each site, by travelling to
each of the three sites and then providing support to the
LHWs in a group, followed by individualised support to
each LHW separately. All lay counsellors completed
grade 12 and have at least one year of prior counselling
experience in TB and/or HIV.
In order to assess the fidelity of the counsellors’ deliv-
ery of motivational interviewing during the trial, the vali-
dated Motivational Interviewing Treatment Integrity
Coding Manual 4.2.1 (MITI) tool will be used [41]. We
will tape record each LHW’s counselling sessions and
then randomly select 5% of each counsellor’s patients
and then use the recordings of all three sessions with
those patients for the MITI task. Those selected record-
ings will be transcribed and translated into English. Two
independent raters who are Setswana/Sesotho speakers
will listen to the recordings and code a randomly se-
lected 20-min portion of the written transcript. In the
case of shorter counselling sessions, the entire recording
will be assessed. The coding will entail making ‘Global
Ratings’ (on four dimensions: Cultivating change talk;
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Softening sustain talk; Partnership; and Empathy) and
‘Behaviour Counts’ (with respect to the items: giving in-
formation; persuade; persuade with permission; question;
simple reflection; complex reflection; affirm; seeking col-
laboration; emphasising autonomy; and confront). A
score will be assigned to each of these items and the
scores compared against the competency and proficiency
thresholds that are specified in the MITI manual.
Economic evaluation
The economic evaluation will be a within-trial incre-
mental cost-effectiveness analysis of the ProLife package
over and above usual care conducted alongside the RCT.
In each arm of the trial, we will estimate the costs of de-
livering the intervention to participants. Costs consist of
the delivery of ProLife intervention (staff costs, over-
heads and consumables) in the intervention arm and the
costs of behavioural support and support (staff time,
overheads and consumables) in the control arm. Costs
will be calculated based on the length of time of contacts
and the unit cost of the healthcare worker delivering the
intervention. These costs should demonstrate some
within patient variability as cost will be partly dependent
upon the length of the recorded appointments.
We will also record contacts with health services for
TB by patients in each trial arm, using the question-
naires adapted from those used in a previous trial of TB
[42]. Applying unit costs of healthcare to quantities re-
corded in the service use questionnaire will produce a
healthcare cost profile for each patient at baseline,
three-month and six-month follow-ups. Healthcare cost
profiles based on TB contacts can then be used to inves-
tigate differences in total costs between the treatment
and control groups. The base case analysis will use
healthcare costs as the study perspective. This is justified
by presenting the cost implications of delivering the
ProLife intervention from a healthcare decision maker’s
perspective. However, we will also record participants’
travel costs associated with making the journey to the
intervention site. This will estimate the wider societal
cost to patients associated with receiving treatment.
We will estimate the cost per additional successful TB
outcome by computing an incremental cost-effectiveness
ratio (ICER) combining treatment and wider healthcare
costs with outcome data from the trial. The analysis will
also use measures of health utility. We have registered on
the EuroQol website to use the country specific version of
EQ-5D-3 L for South Africa to measure health-related
quality of life at baseline, three-month and six-month
follow-ups. We will use EQ-5D-3 L to estimate changes in
quality-adjusted life years (QALY) using the area under
the curve by using the utility score at each time point to
create a profile [41]. A cost utility analysis is then per-
formed by combining incremental health outcomes using
QALYs with the incremental cost. The cost utility analysis
will estimate the cost per QALY that estimates the value
for money afforded by administering the ProLife interven-
tion over and above usual care. We will plot incremental
cost against incremental outcome using a cost-
effectiveness plane. We will also conduct sensitivity ana-
lyses to assess the robustness of the ICER and use boot-
strapping techniques to calculate cost-effectiveness
acceptability curves. Supporting analysis will also present
the costs to patients incurred by making visits to both trial
arms to present the wider cost burden. However, these
costs will not be included in the base case scenario as the
objective is to present the value for money from the per-
spective of the purchaser or commissioner.
Discussion
Ending the TB epidemic is one of the Sustainable
Development Goals (SDG) established by the United
Nations. The WHO calls for a 90% reduction in TB
incidence by 2030 compared to 2015 and has
highlighted the need for intensified research and
innovation. The WHO has recently published guid-
ance advocating the use of digital technologies, spe-
cifically mobile text messaging campaigns, in the
treatment of TB as a means of improving the provision of
patient-centred care and supporting medication adherence
[43]. This publication highlights advances in mobile tech-
nologies and network coverage as opportunities to more
effectively support patients during what can be a long
period of treatment. This study is well-aligned with this
guidance and, to our knowledge, this is the first trial look-
ing at a complex behavioural intervention aiming to use
MI techniques, alongside SMS, to modify a range of
harmful lifestyle factors with the aim of improving TB
treatment outcomes.
Work already undertaken in the formative phase sug-
gests that the ProLife intervention is feasible and accept-
able to patients. However, we anticipate some potential
procedural challenges throughout the trial as we recog-
nise that patients with TB may feel unwell and have
taken steps to ensure that the MI and data collection are
as brief and comfortable for patients as possible. The
district coordinators will call participants to follow-up
with those who missed appointments.
Implementing complex interventions in the real world
can pose logistical challenges and careful process evalu-
ation will be required to fully understand the challenges
that may be presented. However, there is evidence to
suggest that using MI techniques can be cost-effective
when implemented in healthcare settings and the
ProLife programme could represent a scalable and feas-
ible approach to improving the care of patients with TB
globally. Its scalability is particularly relevant in South
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Africa as the government plans to formally introduce
community health workers as part of its health workforce.
Trial status
Protocol Version 1.2, 5 January 2018. Recruitment on-
going; piloting started at 30 clinics: 7 May 2018 and was
completed by 31 August. The actual trial enrolment
started on 13 November 2018. We expect to enrol the
target sample size by May 2019 and plan to continue
with follow-up until December 2019. The trial was
piloted internally from May 2018 until the end of August
2018; piloting results will be reported at a later stage, to-
gether with the trial results.
Additional files
Additional file 1 Participant consent form for screening and for trial.
(DOCX 94 kb)
Additional file 2 Case report form. (DOCX 58 kb)
Additional file 3 Counselling Activities Reporting Form. (DOC 103 kb)
Additional file 4 SPIRIT Checklist. (DOC 120 kb)
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